Purification and characterization of mast cell tryptase and chymase from human tissues.

Alan R McEuen, Andrew F Walls
{"title":"Purification and characterization of mast cell tryptase and chymase from human tissues.","authors":"Alan R McEuen,&nbsp;Andrew F Walls","doi":"10.1007/978-1-59745-366-0_25","DOIUrl":null,"url":null,"abstract":"<p><p>Mast cells are key effector cells of the allergic response. When stimulated by specific allergen through the high-affinity IgE receptors or through other stimuli, these cells release a number of potent mediators of inflammation. Amongst these are the serine proteases tryptase and chymase. In humans, tryptase is the most abundant mediator stored in mast cells. Chymase is present in more moderate amounts in a subpopulation of mast cells (MC(TC)). This subtype of mast cells predominates in connective tissue, whereas the other major subtype, the MC(T), predominates in mucosal tissue. Both proteases have been shown to act on specific extracellular proteins and peptides, as well as to alter the behavior of various cell types. Inhibitors of tryptase have been found to be efficacious in animal and human models of asthma, and both proteases are currently being investigated as potential targets for therapeutic intervention. Such pharmacological, physiological, and biochemical studies require the availability of purified tryptase and chymase. In this chapter, we shall describe procedures for the purification of tryptase and chymase from human tissues and provide protocols for monitoring purification and characterization of the final product. The preparation of recombinant proteases will not be covered, though some of the procedures described may be readily adapted for their purification from recombinant expression systems. The procedures described here have been developed for the purification of the human proteases and will require some modification if applied to purify mast cell proteases from the tissues of other species.</p>","PeriodicalId":18460,"journal":{"name":"Methods in molecular medicine","volume":"138 ","pages":"299-317"},"PeriodicalIF":0.0000,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/978-1-59745-366-0_25","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Methods in molecular medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/978-1-59745-366-0_25","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 10

Abstract

Mast cells are key effector cells of the allergic response. When stimulated by specific allergen through the high-affinity IgE receptors or through other stimuli, these cells release a number of potent mediators of inflammation. Amongst these are the serine proteases tryptase and chymase. In humans, tryptase is the most abundant mediator stored in mast cells. Chymase is present in more moderate amounts in a subpopulation of mast cells (MC(TC)). This subtype of mast cells predominates in connective tissue, whereas the other major subtype, the MC(T), predominates in mucosal tissue. Both proteases have been shown to act on specific extracellular proteins and peptides, as well as to alter the behavior of various cell types. Inhibitors of tryptase have been found to be efficacious in animal and human models of asthma, and both proteases are currently being investigated as potential targets for therapeutic intervention. Such pharmacological, physiological, and biochemical studies require the availability of purified tryptase and chymase. In this chapter, we shall describe procedures for the purification of tryptase and chymase from human tissues and provide protocols for monitoring purification and characterization of the final product. The preparation of recombinant proteases will not be covered, though some of the procedures described may be readily adapted for their purification from recombinant expression systems. The procedures described here have been developed for the purification of the human proteases and will require some modification if applied to purify mast cell proteases from the tissues of other species.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
人组织肥大细胞胰蛋白酶和乳糜酶的纯化和特性研究。
肥大细胞是过敏反应的关键效应细胞。当特异性过敏原通过高亲和力的IgE受体或其他刺激刺激时,这些细胞释放出许多有效的炎症介质。其中包括丝氨酸蛋白酶、胰蛋白酶和乳糜酶。在人类中,胰蛋白酶是储存在肥大细胞中最丰富的介质。Chymase在肥大细胞亚群(MC(TC))中存在的量比较适中。这种肥大细胞亚型主要存在于结缔组织中,而另一种主要亚型MC(T)主要存在于粘膜组织中。这两种蛋白酶已被证明作用于特定的细胞外蛋白和肽,以及改变各种细胞类型的行为。已经发现胰蛋白酶抑制剂在动物和人类哮喘模型中有效,目前正在研究这两种蛋白酶作为治疗干预的潜在靶点。这样的药理学、生理学和生物化学研究需要纯化的胰蛋白酶和酶。在本章中,我们将描述从人体组织中纯化胰蛋白酶和乳糜酶的程序,并提供监测纯化和最终产物表征的方案。重组蛋白酶的制备将不被涵盖,尽管所描述的一些程序可以很容易地适用于从重组表达系统中纯化它们。这里所描述的程序是为纯化人类蛋白酶而开发的,如果应用于从其他物种的组织中纯化肥大细胞蛋白酶,则需要进行一些修改。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Integrating Evolutionary Genetics to Medical Genomics: Evolutionary Approaches to Investigate Disease-Causing Variants Clinical Validation of a Whole Exome Sequencing Pipeline New Perspectives in Personalization of Therapy for Hematological Cancers Molecular Medicines for Parasitic Diseases Landscape Genetics: From Classic Molecular Markers to Genomics
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1